SOD1 and amyotrophic lateral sclerosis: Following these successes, an AAV9 viral vector containing an shRNA targeting mutant SOD1 (AVXS-301) is under pre-clinical development and is expected to be tested in patients with SOD1 ALS in a phase I clinical trial in the near future14.